Elanco Animal Health received approval from the Agriculture Department for Befrena, the company's antibody treatment for canine allergic and atopic dermatitis. The animal-medicine company said ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology ...

Animal Health announced its latest entry into the canine dermatology space with the USDA approval of Befrena, a new anti-IL31 ...

On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with ...

The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...

The company said the results of a planned interim analysis met prespecified criteria for early termination of the study. "They did not meet the high-bar efficacy we established for advancing our ...

Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...

LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company developing first-in-class, orally delivered immune-tolerance-restoring therapies, announced today that the first patient ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

A recently approved injectable eczema drug provides quick itch relief to patients with the maddening skin disease, a new ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...